Cash, cash equivalents, and short-term investments were $84.8 million as of March 31, 2025. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of March 31, 2025, will enable the Company to fund cash flow requirements into the first quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Promising Potential of INZ-701 in Treating ENPP1 Deficiency Drives Buy Rating for Inozyme Pharma
- Inozyme announces JBMR Plus publication on ENPP1 deficiency
- Buy Rating on Inozyme Pharma: Promising Potential of INZ-701 and Market Opportunity